secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001558370-23-013047
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Q2 net loss $22.2M, launches anti-Aβ gene therapy for Alzheimer's
-------------------------------------------------------------------------

- Q2 2023 collaboration revenue $4.9M (up from $0.7M YoY); net loss $22.2M vs $19.1M YoY.
- Cash, equivalents and marketable securities $272.7M as of June 30, 2023; funding into 2025.
- New vectorized anti-Aβ antibody gene therapy research initiative for Alzheimer's disease launched.
- Executed license agreement with Sangamo for prion disease treatment using TRACER capsid.
- VY-TAU01 anti-tau antibody IND on track for H1 2024; GLP tox studies to start in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000155837023013047/0001558370-23-013047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000155837023013047/vygr-20230803x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-013047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer